Tempus AI: Moderna Success with mRNA Cancer Vaccine Triggers Short Squeeze
Reading Time: 3 minutes
Moderna Success: Tempus could directly benefit from the Phase 3 study success of Moderna and Merck with the personalized mRNA cancer vaccine Intismeran. Personalis as a Catalyst: The planned $1.5 billion acquisition positions Tempus as a sequencing provider for personalized mRNA cancer therapies. Stock Rally: The stock rose approximately 24% on Wednesday and gained another nearly 11% on Thursday - a high short position further intensified the movement. Tempus AI (TEM) started a spectacular rally following the historic Phase...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
